today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted ...

Curis' pipeline includes three drugs focused on Heme Malignancies and three on Immune Checkpoint Inhibitors, with updates on their two primary programs expected in 2024. Curis (NASDAQ:CRIS ...

Heme Malignancies Program: TScan’s two lead TCR-T therapy candidates, TSC-100 and TSC-101, are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML ...